KPTI News and Press, Karyopharm Therapeutics Inc. From 07/14/20

Karyopharm Therapeutics (NASDAQ: KPTI ) expects preliminary Q2 net product sales for XPOVIO (selinexor) to be ~$18.5M, (+15% Y/Y), topping Bloomberg average estimate of $17.5M (range $17M to $19M). More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Stocks on the move, ...

-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the  Second Quarter 2020 -- -- Strongest Quarterly XPOVIO Sales Since July 2019 Commercial Launch -- NEWTON, Mass., July 14, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI)...

Karyopharm Therapeutics ( KPTI +5.2% ) perks up, albeit on below-average volume, in apparent response to the release of a briefing document for Tuesday's FDA advisory committee meeting on GlaxoSmithKline's ( GSK -1.0% )  marketing application seeking accelerated approval of antib...

Stocks in the biotechnology sector have outperformed the broader market year to date. Despite the market volatility throughout this year, there are still good prospects in this sector, especially in small-ca p biotechnology stocks. These companies are often selling at attractive prices, and the...

Rhythm Pharmaceuticals Reports Positive Phase 2 Data for Setmelanotide Rhythm Pharmaceuticals Inc. ( RYTM ) announced interim data from its Phase 2 study of Setmelanotide. Under this trial, healthy obese people were administered the weekly formulation of the drug candidate. The trial wa...

Karyopharm is a top idea for several reasons, the lead one being the company's first approved drug Xpovio for multiple myeloma MM, a type of blood cancer. Approved in the U.S. in July 2019, this drug has significant potential in MM and other indications, and with multi-billion-dollar annual s...

Results from a Phase 2 clinical trial, SADAL , evaluating Karyopharm Therapeutics' (NASDAQ: KPTI ) Xpovio (selinexor) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) were just published online in The Lancet Haematology.  More news on: Karyopharm Thera...

NEWTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL ( S elinexor A gainst D iffuse A ggressive L ymphoma) study evaluating XPOVIO in patients with...

Under accelerated review status, the FDA has approved Karyopharm Therapeutics' ( KPTI +4.3% ) Xpovio (selinexor) for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of syste...

-- XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Including DLBCL Arising from Follicular Lymphoma -- -- XPOVIO is the First and Only FDA-Approved Drug for Use in Both M...